[1] Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol 2020;92:401-402.
https://doi.org/10.1002/jmv.25678
[2] Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A. et al. World Health Organization declares Global Emergency: A review of the 2019 Novel Coronavirus (COVID-19). Int J Surg. Int J Surg. 2020;76:71-76. https://doi.org/10.1016/j.ijsu.2020.02.034
[3] World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 13 March2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-mission-briefing-on-covid-19---13-march-2020. Accessed 13 March 2020.
[4] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-475. https://doi.org/10.1016/S0140-6736(20)30317-2
[5] De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-34. https://doi.org/10.1038/nrmicro.2016.81
[6] Wong G, Liu W, Liu Y, Zhou B, Bi Y, Gao G, et al. MERS, SARS, and Ebola: The Role of Super-Spreaders in Infectious Disease. Cell Host Microbe. 2015;18(4):398–401. https://doi.org/10.1016/j.chom.2015.09.013
[7] World Health Organization. MERS monthly summary, November 2019. https://www.who.int/emergencies/mers-cov/en/. Accessed 31 November 2019.
[8] World Health Organization. Ebola virus disease. https://www.who.int/health-topics/ebola#tab=tab. Accessed 31 November 2019.
[9] Arabi YM, Asiri AY, Assiri AM, Jokhdar HAA, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020;21(1):8. https://doi.org/10.1186/s13063-019-3846-x
[10] De Wit E, Feldmann F, Okumura A, Horne E, Haddock E, Saturday G, et al. Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets.Antiviral Res. 2018;156:64-71. https://doi.org/10.1016/j.antiviral.2018.06.006
[11] Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao J, et al. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis. 2018;18(4):410-418. https://doi.org/10.1016/S1473-3099(18)30002-1
[12] Sissoko D, Laouenan C, Folkesson E, M’Lebing AB, Beavogui AH, Baize S, et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016;13(3):e1001967. https://doi.org/10.1371/journal.pmed.1001967
[13] Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019;393(10174):889-898. https://doi.org/10.1016/S0140-6736(19)30036-4
[14] PREVAIL II Writing Group, Multi-National PREVAIL II Study Team, Davey RT Jr, Dodd L, Proschan MA, Neaton J, et al. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N Engl J Med. 2016;375(15):1448-1456. https://doi.org/10.1056/NEJMoa1604330
[15] Mulangu S, Dodd LE, Davey RT, Mbaya OT, Proschan M, MUkadi D, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med, 2019;381(24):2293-2303. https://doi.org/10.1056/NEJMoa1910993
[16] Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019 ;19(9):1013-1022. https://doi.org/10.1016/S1473-3099(19)30266-X
[17] Samai M, Seward JF, Goldstein ST, Mahon BE, Lisk DR, Widdowson MA, et al. The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV∆G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak. J Infect Dis. 2018 ;217(suppl_1):S6-S15. https://doi.org/10.1093/infdis/jiy020
[18] Halperin SA, Arribas JR, Rupp R, Andrews CP, Chu L, Das R, et al. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. J Infect Dis. 2017;215(12):1789-1798. https://doi.org/10.1093/infdis/jix189
[19] Halperin SA, Das R, Onorato MT, Liu K, Martin J, GK RJ, et al. Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults. J Infect Dis. 2019;220(7):1127-1135. https://doi.org/10.1093/infdis/jiz241
[20] Regules JA, Beigel JH, Paolino KM, Voell J, Castellano A, Hu Z, et al. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med. 2017;376(4):330-341. https://doi.org/10.1056/NEJMoa1414216
[21] World Health Organization. Four countries in the African region license vaccine in milestone for Ebola prevention. https://www.who.int/news-room/detail/14-02-2020-four-countries-in-the-african-region-license-vaccine-in-milestone-for-ebola-prevention. Accessed 14 February 2020.
[22] Van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med. 2016;374(1):33-42. https://doi.org/10.1056/NEJMoa1511812
[23] Van Griensven J, Edwards T, Baize S, Consortium E. Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies. N Engl J Med. 2016;375(23):2307-2309. https://doi.org/10.1056/NEJMc1609116
[24] Garraud O. Use of convalescent plasma in Ebola virus infection. Transfus Apher Sci. 2017;56(1):31-34. https://doi.org/10.1016/j.transci.2016.12.014
[25] Yang Y, Li W, Zhang Q, Zhang L, Cheung T, Xiang Y. Mental health services for older adults in China during the COVID-19 outbreak. Lancet Psychiatry. 2020;S2215-0366(20)30079-1. https://doi.org/10.1016/S2215-0366(20)30079-1
[26] Chen Q, Liang M, Li Y, Guo J, Fei D, Wang L, et al. Mental health care for medical staff in China during the COVID-19 outbreak. Lancet Psychiatry. 2020;S2215-0366(20)30078-X. https://doi.org/10.1016/S2215-0366(20)30078-X
[27] Liu X, Zhang M, He L, Li Y. Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS). Cochrane Database Syst Rev. 2012;10(10):CD004882. https://doi.org/10.1002/14651858.CD004882.pub3
[28] More than 80 clinical trials launch to test coronavirus treatments. Nature. 2020. https://www.nature.com/articles/d41586-020-00444-3. Accessed 15 February 2020.
[29] Chen J, Ling Y, Xi X, Liu P, Li F, Li T, et al. Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia. Chinese Journal of Infectious Diseases,2020,38(00): E008-E008. https://doi.org/10.3760/cma.j.cn311365-20200210-00050.
[30] B. Cao, Y. Wang, D. Wen, W. Liu, Jingli Wang, G. Fan, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. The New England Journal of Medicine. 2020. March 18, 2020https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true
[31] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. https://doi.org/10.1038/s41422-020-0282-0.
[32] Wang H, Wang Q. Advances in research of novel coronavirus (COVID-19) related drugs and biological products. Acta Pharmaceutica Sinica. 2020;2020-03-17:1-13. http://kns.cnki.net/kcms/detail/11.2163.R.20200226.1702.007.html.
[33] Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce J, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929-936. https://doi.org/10.1056/NEJMoa2001191
[34] Xiang Y, ZENG C, HUANG Z, Wang X, Zhang Z, Yang G. Analysis of clinical trial registration information of COVID-19 in China. Chin J Clin Pharmacol Ther. 2020;2020-03-17:1-6. https://kns.cnki.net/KCMS/detail/34.1206.R.20200304.1222.002.html
[35] Ministry of science and technology of the People's Republic of China. The research team of the joint prevention and control mechanism of new coronavirus pneumonia under the state council of China issued “the notice on standardizing medical institutions to carry out clinical research on drug treatment of new coronavirus pneumonia”
http://www.most.gov.cn/tztg/202002/t20200225_151897.htm. Accessed 25 February 2020.